Endocrinology Research and Practice
Review Article

Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

1.

MedAmerikan Medical Center, İstanbul, Turkey

2.

Department of Endocrinology and Metabolism, Yeditepe University Faculty of Medicine, İstanbul, Turkey

3.

Department of Endocrinology and Metabolism, Akdeniz University Faculty of Medicine, Antalya, Turkey

4.

Department of Endocrinology and Metalobism, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey

5.

Department of Endocrinology and Metabolism, İstanbul University İstanbul Faculty of Medicine, İstanbul, Turkey

6.

Department of Endocrinology and Metabolism, Hacettepe University Faculty of Medicine, Ankara, Turkey

7.

Department of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

8.

Department of Endocrinology and Metabolism, Marmara University Faculty of Medicine, İstanbul, Turkey

9.

Department of Endocrinology and Metabolism, Ankara University Faculty of Medicine, Ankara, Turkey

10.

Department of Endocrinology and Metabolism, İnönü University Faculty of Medicine, Malatya, Turkey

11.

Department of Endocrinology and Metabolism, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Turkey

12.

Department of Endocrinology and Metabolism, Erciyes University Faculty of Medicine, Kayseri, Turkey

Turk J Endocrinol Metab 2018; 22: 183-197
DOI: 10.25179/tjem.2017-57420
Read: 630 Downloads: 161 Published: 01 September 2018

ABSTRACT

The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin insufficiency and/or insulin resistance, delay beta cell damage/depletion, and prevent other metabolic co-morbidities and complications. In the current treatment algorithms, lifestyle changes (medical nutrition therapy, physical exercise) and oral anti-diabetics are followed by insulin therapy, which is considered a replacement therapy for Type 2 diabetes. Pre-mixed insulin preparations, which are an option for patients with poor blood glucose level control under oral anti-diabetics treatment, have been developed to meet both basal and prandial insulin needs by simulating the physiological changes in insulin levels. The consensus on the necessity of individualizing insulin therapy requires physicians to have a detailed knowledge of the various uses of insulin. Therefore, this comprehensive consensus statement has been prepared by a panel of expert endocrinologists from different regions of Turkey to help physicians use biphasic insulin aspart 30 in suitable patients at the right time. In this statement, expert panel opinions on (a) Recommendations for the appropriate initiation, titration, and intensification of insulin treatment, and (b) The treatment algorithms in initiation, titration, and intensification of biphasic insulin aspart 30 treatment and special conditions specific to changing treatment regimen are presented.

 

Files
TURKISH